



Canadian Journal of  
Cardiology

Journal canadien  
de cardiologie

www.onlinecjc.ca

*Journal of the  
Journal de la*



Canadian  
Cardiovascular  
Society

Société  
canadienne  
de cardiologie

For Issue Highlights with article summaries, go to [www.onlinecjc.ca](http://www.onlinecjc.ca).

## Editorial

**547** Guideline Implications of Prothrombotic State Assessment in Low-Risk Atrial Fibrillation Patients: Consistency With CHA<sub>2</sub>DS<sub>2</sub>-VASc and Support for CHADS-65

*Stanley Nattel, MD, and Gregory Y.H. Lip, MD*

**550** To Risk Stratify or Not for Statin Therapy

*David Fitchett, MD, FRCP(C), FESC*

**552** Women in Cardiovascular Clinical Trials—What Are the Barriers to Address to Improve Enrollment?

*Christine Pacheco, MD, and C. Noel Bairey Merz, MD*

**555** Muscarinic Receptor Type-3 in Hypertension and Cholinergic-Adrenergic Crosstalk: Genetic Insights and Potential for New Antihypertensive Targets

*Rhêure Alves-Lopes, PhD, Karla B. Neves, PhD, and Rhian M. Touyz, MD, PhD*

**558** The 2018 ACC/AHA Lipid Guidelines: A Little More or Less Canadian?

*George Thanassoulis, MD, Jean Gregoire, MD, and Glen J. Pearson, BScPhm, PharmD*

## Viewpoint

**564** Hypertension Guidelines: Effect of Blood Pressure Targets

*Rhian M. Touyz, MD, PhD*

Publication Mail Agreement 41536048  
Return undeliverable Canadian addresses to:  
Elsevier  
Periodicals Order  
Fulfillment Department  
1799 Highway 50 East  
Linn, MO 65051

Printed in Canada

### On the Cover: *Lipids, Lipids, Lipids!*

*This cover artwork features a cross section of a lipoprotein with pills and molecules floating in the background to represent pharmacological management. From lipids in the blood to the formation of atherosclerosis in the walls of arteries, this cover art captures a key topic in pathophysiology of vascular disease and cardiovascular health. Original artwork by Michiko Maruyama.*

Continued

## Table of Contents

### Review

#### 570 Evolution of Blood Pressure Clinical Practice Guidelines: A Personal Perspective

*Paul K. Whelton, MB, MD, MSc*

#### 582 The History of Hypertension Guidelines in Canada

*Stella S. Daskalopoulou, MD, PhD, Ross D. Feldman, MD, Finlay A. McAlister, MD, MSc, and Doreen M. Rabi, MD, MSc; on behalf of Hypertension Canada*

#### 590 Cholesterol Lowering Guidelines: From Whence We Came and Where We Are Now

*David D. Waters, MD*

#### 598 Sex-Specific Considerations in Guidelines Generation and Application

*Cara Tannenbaum, MD, MSc, Colleen M. Norris, BScN, MScN, PhD, and M. Sean McMurry, MD, PhD*

#### 606 Guideline Alignment in Related Areas

*Lisa Dubrofsky, MDCM, FRCPC, and Sheldon W. Tobe, MD, MSc CH (HPTE), FRCPC, FACP, FASH*

#### 611 Importance of Risk Reassessment in Patients With Atrial Fibrillation in Guidelines: Assessing Risk as a Dynamic Process

*Ting-Yung Chang, MD, Gregory Y.H. Lip, MD, Shih-Ann Chen, MD, and Tze-Fan Chao, MD*

#### 619 Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines

*Marco Proietti, MD, PhD, Deirdre A. Lane, PhD, Giuseppe Boriani, MD PhD, and Gregory Y.H. Lip, MD*

### Clinical Research

#### 634 Prothrombotic State in Atrial Fibrillation Patients With One Additional Risk Factor of the CHA<sub>2</sub>DS<sub>2</sub>-VASc Score (Beyond Sex)

*Błażej Głowicki, MD, Paweł T. Matusik, MD, PhD, Krzysztof Plens, MSc, and Anetta Undas, MD, PhD*

#### 644 Statin Use in Primary Prevention: A Simple Trial-Based Approach Compared With Guideline-Recommended Risk Algorithms for Selection of Eligible Patients

*Kamlesh Khunti, MD, PhD, Hyejung Jung, MSc, Antonio L. Dans, MD, Claes Held, MD, PhD, Gilles R. Dagenais, MD, Salim Yusuf, MB, BS, DPhil, and Eva Lonn, MD*

#### 653 Temporal Trends of Women Enrollment in Major Cardiovascular Randomized Clinical Trials

*Inna Y. Gong, MD, PhD, Nigel S. Tan, MD, Sammy H. Ali, MD, Gerald Lebovic, PhD, Muhammad Mamdani, PharmD, MA, MPH, Shaun G. Goodman, MD, MSc, Dennis T. Ko, MD, MSc, Andreas Laupacis, MD, MSc, and Andrew T. Yan, MD*

---

## Table of Contents

---

### Basic Research

**661** Functional Dosage of Muscarinic Cholinergic Receptor 3 Signalling, Not the Gene Dose, Determines Its Hypertension Pathogenesis

*Alan Y. Deng, PhD, Julie-Émilie Huot-Marchard, PhD, Denis deBlois, PhD, Eric Thorin, PhD, Cristina Chauvet, PhD, and Annie Menard, MS*

### Letters to the Editor

**671.e1** Dietary Sodium and the Health of Canadians ☒

*Norm R.C. Campbell, MD, Simon Bacon, PhD, Andrew Pipe, MD, Sherry L. Grace, PhD, Manuel Arango, MA, MPH, Kim Raine, PhD, and Janusz Kaczorowski, PhD*

### Departments

**A10** Information for Readers